Repare Therapeutics Inc.

NasdaqGS RPTX

Repare Therapeutics Inc. Cash and Short-Term Investments for the year ending December 31, 2023: USD 223.63 M

Repare Therapeutics Inc. Cash and Short-Term Investments is USD 223.63 M for the year ending December 31, 2023, a -34.98% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.

Repare Therapeutics Inc. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 343.94 M, a 0.61% change year over year.
Repare Therapeutics Inc. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 341.87 M, a 2.44% change year over year.
Repare Therapeutics Inc. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 333.71 M, a 252.03% change year over year.
Repare Therapeutics Inc. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 94.80 M, a 783.39% change year over year.

Key data

Date	Cash and Short-Term Investments	Receivables	Inventory	Goodwill

NasdaqGS: RPTX

Repare Therapeutics Inc.

CEO	Mr. Lloyd Mitchell Segal
IPO Date	June 19, 2020
Location	Canada
Headquarters	7210 Frederick-Banting
Employees	179
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Key trends

Past 5 years